Smoking status and the baseline international index of erectile function score can predict satisfactory response to platelet‐rich plasma in patients with erectile dysfunction: A prospective pilot study

Andrologia ◽  
2021 ◽  
Author(s):  
Ahmed Said Zaghloul ◽  
Abd El Rahman Mahmoud ElNashar ◽  
Sameh Fayek GamalEl Din ◽  
Shady Zaki Said ◽  
Hany Mohammed Saad ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Pilot Study ◽  
Erectile Function ◽  
Platelet Rich Plasma ◽  
Smoking Status ◽  
Function Score ◽  
Satisfactory Response ◽  
Prospective Pilot Study

scholarly journals COMBINATION OF PLATELET RICH PLASMA, LOWINTENSITY PULSED ULTRASOUND AND SILDENAFIL ORAL SPRAY IN TREATMENT OF ERECTILE DYSFUNCTION

2019 ◽  
pp. 42-49
Author(s):  
Yurii Zasieda
Keyword(s):  
Erectile Dysfunction ◽  
Growth Factors ◽  
Erectile Function ◽  
Platelet Rich Plasma ◽  
Treatment Protocol ◽  
Main Group ◽  
Control Group ◽  
Pulsed Ultrasound ◽  
Stimulation Of ◽  
Intracavernous Injections

Relevance. Some non-pharmacological methods, such as low-intensity pulsed ultrasound (LIPUS) proved to be effective in ED treatment due to stimulation of penile tissue regeneration and penile hemodynamics increase. The biological methods that utilize cellular growth factors such as platelet-rich plasma (PRP) therapy proved to be effective in stimulation of neovascularization processes and correction of endothelial dysfunction while ED treatment.Local negative pressure (LNP) therapy shall be considered as an auxiliary method to PRP and LIPUS due to its ability to slow down PRP outflow from injection zones. Sildenafil («Strondex») is perspective pharmacological addition to ED treatment protocol. Aim. Evaluation of the efficacy and safety of therapeutic model of combined application of PRP intracavernous injections, LNP, LIPUS and Sildenafil («Strondex») for vasculogenic (arterial and corporal veno-occlusive) ED treatment.Materials and methods. Prospective study was conducted in a group of 64 outpatients with diagnosis of erectile dysfunction of vascular genesis (ICD-10: N48.4) in Men’s Health Clinic (Kyiv, Ukraine). “International Index of Erectile Function-5” (IIEF-5), “Erectile Hardness Score” (EHS) were used as the tools for clinical assessment. Ultrasonic cavernous bodies scanning and pharmacodopplersonography were used for the data validation.Study results. Main group patients underwent treatment consisting of 6 sessions of PRP intracavernous injections and 12 sessions of local penile LIPUS combined with LNP and Sildenafil («Strondex») pharmacotherapy. Control group underwent 12 sessions of local penile LIPUS combined with LNP and the same pharmacotherapy. According to the IIEF-5 data obtained 12 weeks after the study the erectile function improvement was found in 27 patients of the main group and 20 patients of the control group. EHS improved by 1 point or more in 29 and 20 patients correspondingly.Conclusions. Treatment protocol specifying combination of PRP, LIPUS, LNP and Sildenafil («Strondex») is promising due to PRP-therapy augmentation by intracavernous ultrasonic activation of platelet growth factors, but the data obtained require further physiological validation and clinical placebo-controlled studies with involvement of larger groups of population.

Prospective Pilot Study of Sildenafil for Treatment of Postradiotherapy Erectile Dysfunction in Patients With Prostate Cancer

1999 ◽  
Vol 17 (11) ◽  
pp. 3444-3449 ◽  
Author(s):  
Damien C. Weber ◽  
Sabine Bieri ◽  
John M. Kurtz ◽  
Raymond Miralbell
Keyword(s):  
Prostate Cancer ◽  
Erectile Dysfunction ◽  
Pilot Study ◽  
Sexual Intercourse ◽  
External Beam Radiotherapy ◽  
Late Complication ◽  
Prospective Trial ◽  
External Beam ◽  
Prospective Pilot Study ◽  
Patient Reported

PURPOSE: Erectile dysfunction is a common late complication patients may experience after external-beam radiotherapy for prostate cancer. The efficacy and safety of oral sildenafil to correct sexual dysfunction caused by external-beam radiotherapy was studied in patients participating in our prospective trial. PATIENTS AND METHODS: Thirty-five assessable patients participated in this prospective pilot study. Using a 25-point scale based on the International Index of Sexual Function, erectile dysfunction was assessed weekly, during which time patients received sildenafil 100 mg orally once a week for 6 consecutive weeks. Response was defined as a score of 18 or more, corresponding to at least one successful attempt at sexual intercourse per week. RESULTS: Thirty patients (86%) completed the 6-week study. Seventy-seven percent of these patients had significantly improved erectile function, allowing recovery of full capacity for sexual intercourse. Of 27 patients not receiving concomitant hormone treatment, failure to respond was observed in only four patients (15%) compared with four (50%) of eight patients receiving hormonal treatment during the study. The time course of response was gradual, with 40%, 57%, 66%, 69%, and 74% responding at weeks 1 through 5, respectively. Therapy was generally well tolerated. The most frequently reported side effects in patients were flushing (37%), transient headache (17%), and dyspepsia (9%). No patient reported priapism, and no cardiovascular event or death was observed. After response, 12 patients (34%) reported the ability to achieve and maintain an erection sufficient for intercourse in the absence of sildenafil (ie, 24 hours to 6 days after taking the medication). CONCLUSION: This study suggests that oral sildenafil is well tolerated and can reverse erectile dysfunction after radiotherapy in a substantial proportion of prostate cancer patients.

scholarly journals Effect of Low-Dose Tadalafil Once Daily On Glycemic Control In Patients With Type 2 Diabetes and Erectile Dysfunction: A Randomized, Double-blind, Placebo-controlled Pilot Study

2021 ◽  
Author(s):  
Min-Kyung Lee ◽  
Jae-Hyuk Lee ◽  
Seo-Young Sohn ◽  
Seo Yeon Lee ◽  
Tae-Yoong Jeong ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Erectile Dysfunction ◽  
Placebo Group ◽  
Pilot Study ◽  
Erectile Function ◽  
Hba1c Level ◽  
Low Dose ◽  
Double Blind ◽  
Double Blind Placebo

Abstract Background: Phosphodiesterase type 5 inhibitors restore nitric oxide signaling, which plays a significant role in erectile function and appears to counteract insulin resistance in animal and human models. This study was aimed to evaluate the glycemic and metabolic effects of low-dose tadalafil once a day in patients with type 2 diabetes and erectile dysfunction.Methods: A 6-month, randomized, double-blind, placebo-controlled pilot trial was conducted. Eligible patients were randomly assigned in a ratio of 2:1 to the tadalafil 5 mg and placebo groups; all patients received either tadalafil or placebo once a day. The primary efficacy endpoint was the change in the glycated hemoglobin (HbA1c) level during the 6-month study period. The secondary efficacy endpoints included metabolic parameters and erectile function. Results: Of the 68 patients who completed this study, 45 and 23 patients were allocated in the tadalafil and placebo groups, respectively. The mean HbA1c level was significantly different between the groups over the 6-month study period (P = 0.021). After 6 months of treatment, the HbA1c decrement in the tadalafil group was greater than that in the placebo group (-0.14% ± 0.53% vs. 0.20% ± 0.69%, P = 0.030). The improvement in the International Index of Erectile Function-5 scores were significantly greater in the tadalafil group than in the placebo group at 6 months (P = 0.003). Conclusion: This prospective pilot study shows that low-dose tadalafil once a day is effective in improving glycemic control and erectile function in patients with type 2 diabetes and erectile dysfunction.Trial Registration: KCT0005666

scholarly journals Administration of Adipose Derived Mesenchymal Stem Cells and Platelet Lysate in Erectile Dysfunction: A Single Center Pilot Study

2019 ◽  
Vol 6 (1) ◽  
pp. 21 ◽  
Author(s):  
Vassilis Protogerou ◽  
Efstathios Michalopoulos ◽  
Panagiotis Mallis ◽  
Ioanna Gontika ◽  
Zetta Dimou ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Adipose Tissue ◽  
Erectile Dysfunction ◽  
Pilot Study ◽  
Erectile Function ◽  
Platelet Lysate ◽  
Negative Effects ◽  
Significant Difference ◽  
Group A

Erectile dysfunction (ED) affects more than 30 million men; endothelial dysfunction plays a significant role in EDs pathogenesis. The aim of this study was to administer mesenchymal stem cells (MSC) derived from adipose tissue and platelet lysate (PL) into patients with erectile dysfunction. This pilot study enrolled eight patients with diagnosed ED. Patients enrolled were suffering from organic ED due to diabetes melitus, hypertension, hypercholesterolaemia, and Peyronie disease. The patients were distributed in 2 groups. Patients in group A received adipose derived mesenchymal stem cells (ADMSC) resuspended in PL while patients in group B received only PL. ADMSCs were isolated from patients’ adipose tissue and expanded. In addition, blood sampling was obtained from the patients in order to isolate platelet lysate. After the application of the above treatments, patients were evaluated with an International Index of Erectile Function (IIEF-5) questionnaire, penile triplex, and reported morning erections. After MSCs and PL administration, patients presented improved erectile function after 1 and 3 months of follow-up. A statistically significant difference was observed in the IIEF-5 score before and after administration of both treatments after the first month (p < 0.05) and the third month (p < 0.05). No statistically significant difference was observed in the IIEF-5 score between group A and B patients. All patients were characterized by improved penile triplex and increased morning erections. No severe adverse reactions were observed in any patient except a minor pain at the site of injection, which was in the limits of tolerability. The results of this study indicated the satisfactory use of MSCs and PL in ED. MSCs in combination with PL or PL alone seems to be very promising, especially without having the negative effects of the current therapeutic treatment.

Sign in / Sign up

Export Citation Format

Share Document